Meet Cromos Pharma’s CEO, Dr. Vlad Bogin in San Antonio, Texas at San Antonio Breast Cancer Symposium (SABCS 2016) on December 6-10, 2016
Cromos™ Pharma helps Regen Biopharma in filing of an Investigational New Drug (IND) application with the FDA Regen BioPharma announced today filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company’s HemaXellerate I™ stem cell drug in patients with drug-refractory aplastic anemia. Cromos Pharma’s team took active part in IND application preparation. More details can be found at Regen Biopharma website and press-release.
Meet Cromos Pharma’s CEO, Dr. Vlad Bogin in San Antonio, Texas at San Antonio Breast Cancer Symposium (SABCS 2016) on December 6-10, 2016
CEO, Dr. Vlad Bogin collaborates on a scientific publication describing new gene responsible for heart damage in diabetics BACKGROUND: Apoptosis is an early event involved in cardiomyopathy associated with diabetes mellitus. Toll-like receptor (TLR) signaling triggers cell apoptosis through multiple mechanisms. Up-regulation of TLR4 expression has been shown in diabetic mice. This study aimed to delineate the role of TLR4 in myocardial apoptosis, and to block this process through gene silencing of TLR4
Meet Cromos Pharma’s CEO, Dr. Vlad Bogin in San Antonio, Texas at San Antonio Breast Cancer Symposium (SABCS 2016) on December 6-10, 2016
Cromos Pharma profiled in The Top 20 Contract Research Organizations in Europe in Research and Markets “The CRO industry in Europe is predicted to experience double-digit growth over the next five years due to both growth in drug development and the increasing use of outsourcing by pharmaceutical, biotechnology and medical device companies. There are several hundred Contract Research Organisations in Europe. This report profiles the Top 100 of them. These companies

Schedule a meeting

We are excited to connect with you, understand your goals, and explore how we can support your needs.

Contact us